Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $50,830 | 36 | 67.0% |
| Honoraria | $9,475 | 6 | 12.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $9,271 | 3 | 12.2% |
| Charitable Contribution | $2,500 | 1 | 3.3% |
| Travel and Lodging | $2,045 | 10 | 2.7% |
| Food and Beverage | $1,223 | 14 | 1.6% |
| Education | $507.48 | 2 | 0.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Valneva Usa, Inc. | $26,501 | 27 | $0 (2024) |
| Valneva Austria GMBH | $24,675 | 20 | $0 (2024) |
| Merck Sharp & Dohme LLC | $10,965 | 14 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $5,100 | 1 | $0 (2024) |
| Bavarian Nordic A/S | $4,035 | 3 | $0 (2024) |
| SANOFI PASTEUR INC. | $3,322 | 2 | $0 (2021) |
| Emergent BioSolutions Inc. | $1,088 | 1 | $0 (2021) |
| Sirtex Medical Inc | $117.88 | 1 | $0 (2021) |
| ARBOR PHARMACEUTICALS, INC. | $28.33 | 2 | $0 (2019) |
| La Jolla Pharmaceutical Company | $18.96 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $20,741 | 18 | Valneva Usa, Inc. ($6,313) |
| 2023 | $12,434 | 18 | Valneva Austria GMBH ($5,700) |
| 2022 | $12,082 | 12 | Valneva USA, Inc. ($7,027) |
| 2021 | $18,428 | 14 | Valneva USA, Inc. ($7,600) |
| 2020 | $3,000 | 3 | Valneva Austria GmbH ($3,000) |
| 2019 | $2,692 | 4 | Valneva USA, Inc. ($2,664) |
| 2017 | $6,475 | 3 | Valneva Austria GmbH ($6,475) |
All Payment Transactions
72 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/21/2024 | Valneva Usa, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,204.93 | General |
| 08/21/2024 | Valneva Usa, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,074.63 | General |
| 08/21/2024 | Valneva Usa, Inc. | — | Consulting Fee | Cash or cash equivalent | $556.12 | General |
| 07/11/2024 | Valneva Usa, Inc. | — | Consulting Fee | Cash or cash equivalent | $467.07 | General |
| 06/03/2024 | Merck Sharp & Dohme LLC | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,255.00 | General |
| 06/03/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 06/01/2024 | Bavarian Nordic A/S | Encepur (Drug) | Consulting Fee | Cash or cash equivalent | $3,528.00 | General |
| Category: Vaccines | ||||||
| 05/21/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $372.89 | General |
| 05/21/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $113.94 | General |
| 04/18/2024 | Valneva Usa, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,013.64 | General |
| 04/18/2024 | Valneva Usa, Inc. | — | Consulting Fee | Cash or cash equivalent | $737.19 | General |
| 04/12/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $5,100.00 | General |
| 03/13/2024 | Bavarian Nordic A/S | — | Education | Cash or cash equivalent | $167.47 | General |
| 02/05/2024 | Bavarian Nordic A/S | — | Education | Cash or cash equivalent | $340.01 | General |
| 01/11/2024 | Valneva Austria GMBH | IXCHIQ (Drug) | Consulting Fee | Cash or cash equivalent | $1,400.00 | General |
| Category: Vaccine | ||||||
| 01/11/2024 | Valneva Usa, Inc. | — | Consulting Fee | Cash or cash equivalent | $539.86 | General |
| 01/11/2024 | Valneva Usa, Inc. | — | Consulting Fee | Cash or cash equivalent | $359.91 | General |
| 01/11/2024 | Valneva Usa, Inc. | — | Consulting Fee | Cash or cash equivalent | $359.91 | General |
| 11/08/2023 | Valneva Usa, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,250.00 | General |
| 11/02/2023 | Valneva Austria GMBH | — | Consulting Fee | Cash or cash equivalent | $1,600.00 | General |
| 10/23/2023 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $2,790.00 | General |
| 10/23/2023 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 10/18/2023 | Valneva Usa, Inc. | — | Travel and Lodging | Cash or cash equivalent | $339.26 | General |
| 10/18/2023 | Valneva Usa, Inc. | — | Food and Beverage | Cash or cash equivalent | $171.60 | General |
| 10/17/2023 | Valneva Usa, Inc. | — | Food and Beverage | Cash or cash equivalent | $126.08 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 2 | 264 | 264 | $18,010 | $13,424 |
| 2021 | 4 | 432 | 432 | $29,222 | $18,228 |
| 2020 | 3 | 574 | 574 | $38,967 | $22,614 |
All Medicare Procedures & Services
9 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90662 | Influenza vaccine split virus, preservative free | Office | 2022 | 130 | 130 | $11,310 | $8,910 | 78.8% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 134 | 134 | $6,700 | $4,514 | 67.4% |
| 90662 | Vaccine for influenza for injection into muscle, split virus, preservation free | Office | 2021 | 176 | 176 | $15,312 | $11,486 | 75.0% |
| G0008 | Administration of influenza virus vaccine | Office | 2021 | 215 | 215 | $10,750 | $4,199 | 39.1% |
| 90694 | Influenza virus vaccine, quadrivalent (aiiv4), inactivated, adjuvanted, preservative free, for injection into muscle, 0.5 ml dosage | Office | 2021 | 30 | 30 | $2,610 | $1,993 | 76.4% |
| 90682 | Vaccine for influenza derived from dna for injection into muscle, quadrivalent, preservative and antibiotic free | Office | 2021 | 11 | 11 | $550.00 | $550.00 | 100.0% |
| 90662 | Vaccine for influenza for injection into muscle | Office | 2020 | 276 | 276 | $24,012 | $16,830 | 70.1% |
| G0008 | Administration of influenza virus vaccine | Office | 2020 | 287 | 287 | $14,350 | $5,462 | 38.1% |
| 90674 | Vaccine for influenza for administration into muscle, 0.5 ml dosage | Office | 2020 | 11 | 11 | $605.00 | $321.53 | 53.1% |
About Dr. Lin Chen, MD
Dr. Lin Chen, MD is a Infectious Disease healthcare provider based in Cambridge, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/15/2005. The National Provider Identifier (NPI) number assigned to this provider is 1285636654.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Lin Chen, MD has received a total of $75,852 in payments from pharmaceutical and medical device companies, with $20,741 received in 2024. These payments were reported across 72 transactions from 10 companies. The most common payment nature is "Consulting Fee" ($50,830).
As a Medicare-enrolled provider, Chen has provided services to 1,270 Medicare beneficiaries, totaling 1,270 services with total Medicare billing of $54,265. Data is available for 3 years (2020–2022), covering 9 distinct procedure/service records.
Practice Information
- Specialty Infectious Disease
- Location Cambridge, MA
- Active Since 08/15/2005
- Last Updated 04/09/2009
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1285636654
Products in Payments
- Encepur (Drug) $3,528
- IXIARO (Biological) $2,664
- IXCHIQ (Drug) $1,400
- SIR-Spheres Microspheres (Device) $117.88
- Edarbi (Drug) $28.33
- XERAVA (Drug) $18.96
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Cambridge
Michael Callahan, M.d, M.D
Infectious Disease — Payments: $517,547
Dr. Stephen Zinner, Md, MD
Infectious Disease — Payments: $97,066
Dr. Bruce Walker, Md, MD
Infectious Disease — Payments: $54,326
Dr. Vito Iacoviello, Md, MD
Infectious Disease
Dr. John Tully, Md, MD
Infectious Disease
Dr. Robert Colgrove, Md, MD
Infectious Disease